“Growing Focus on Precision Medicine”
A significant trend in the pemigatinib market is the increasing emphasis on precision medicine, particularly in treating advanced cholangiocarcinoma. Pemigatinib, a selective inhibitor of fibroblast growth factor receptors (FGFRs), has been specifically developed for patients with FGFR2 fusions or mutations. For instance, the FDA approval of pemigatinib (brand name Pemazyre) in April 2020 marked a milestone in personalized cancer therapy, addressing an unmet need for targeted treatment options. This focus on precision medicine is driving research and development efforts, leading to combination therapies and expanded indications, thereby enhancing patient outcomes and supporting market growth in oncology therapeutics.
